Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G. Solini A, et al. Among authors: galli l. Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926. Oncotarget. 2015. PMID: 26337470 Free PMC article.
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Galli L, Fontana A, Galli C, Landi L, Fontana E, Antonuzzo A, Andreuccetti M, Aitini E, Barbieri R, Di Marsico R, Falcone A. Galli L, et al. Among authors: galli c. Br J Cancer. 2007 Dec 17;97(12):1613-7. doi: 10.1038/sj.bjc.6604090. Epub 2007 Nov 20. Br J Cancer. 2007. PMID: 18026196 Free PMC article. Clinical Trial.
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G. Fontana A, et al. Among authors: galli l, galli c. Clin Cancer Res. 2009 Aug 1;15(15):4954-62. doi: 10.1158/1078-0432.CCR-08-3317. Epub 2009 Jul 21. Clin Cancer Res. 2009. PMID: 19622584 Clinical Trial.
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G. Orlandi P, et al. Among authors: galli l. Br J Cancer. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860526 Free PMC article.
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Derosa L, et al. Among authors: galli l. Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8. Cancer. 2014. PMID: 25111199 Free article. Clinical Trial.
1,153 results